Levamlodipine
- Generic Name
- Levamlodipine
- Brand Names
- Conjupri
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 103129-82-4
- Unique Ingredient Identifier
- 0P6NLP6806
- Background
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interc...
- Indication
Levamlodipine is indicated alone or in combination to treat hypertension in adults and children.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Anti Inflammatory Treatment of Hypertension
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-02-05
- Target Recruit Count
- 200
- Registration Number
- NCT04740840
CKD-828 (80/5mg) Pharmacokinetic Study
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT02358824
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, samdeok-dong, 2-ga 50, samdeok-dong, 2-ga 50 Jung-gu, Korea, Republic of
CKD-828 (80/5mg) Pharmacokinetic Study
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 69
- Registration Number
- NCT02250833
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, samdeok-dong, 2-ga 50, samdeok-dong, 2-ga 50 Jung-gu, Korea, Republic of
CKD-828 Primary Hypertension Trial(Dose-selection)
- Conditions
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 430
- Registration Number
- NCT01128322
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷DonGuk University International Hospital, Goyang, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.